Prelude Therapeutics Inc — Director's Dealing 2023

Feb 9, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Prelude Therapeutics Inc (PRLD)
CIK: 0001678660
Period of Report: 2023-02-07

Reporting Person: Vaddi Krishna (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-02-07	Employee Stock Option (right to buy)	$7.20	A	330000.00	Acquired	2033-02-06	Common Stock (330000.00)	Direct

Footnotes

F1: The stock option vests as to 25% of the total shares on February 7, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.